Issue 11, 2022

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

Abstract

The antibody–drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose of treating cancer. However, antibody-mediated delivery (AMD) remains inefficient, limiting its applicability to targeting highly potent payloads to cells with high antigen expression. Maximizing the number of payloads delivered per antibody is one key way in which delivery efficiency can be improved, although this has been challenging to carry out; with few exceptions, increasing the drug-to-antibody ratio (DAR) above ∼4 typically destroys the biophysical properties and in vivo efficacy for ADCs. Herein, we describe the development of a novel bioconjugation platform combining cysteine-engineered (THIOMAB) antibodies and recombinant XTEN polypeptides for the unprecedented generation of homogeneous, stable “TXCs” with DAR of up to 18. Across three different bioactive payloads, we demonstrated improved AMD to tumors and Staphylococcus aureus bacteria for high-DAR TXCs relative to conventional low-DAR ADCs.

Graphical abstract: A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

Supplementary files

Article information

Article type
Edge Article
Submitted
22 9 2021
Accepted
27 1 2022
First published
28 1 2022
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY-NC license

Chem. Sci., 2022,13, 3147-3160

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

N. Zacharias, V. N. Podust, K. K. Kajihara, D. Leipold, G. Del Rosario, D. Thayer, E. Dong, M. Paluch, D. Fischer, K. Zheng, C. Lei, J. He, C. Ng, D. Su, L. Liu, S. Masih, W. Sawyer, J. Tinianow, J. Marik, V. Yip, G. Li, J. Chuh, J. H. Morisaki, S. Park, B. Zheng, H. Hernandez-Barry, K. M. Loyet, M. Xu, K. R. Kozak, G. L. Phillips, B. Shen, C. Wu, K. Xu, S. Yu, A. Kamath, R. K. Rowntree, D. Reilly, T. Pillow, A. Polson, V. Schellenberger, W. L. W. Hazenbos and J. Sadowsky, Chem. Sci., 2022, 13, 3147 DOI: 10.1039/D1SC05243H

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements